Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX – Free Report) – Analysts at HC Wainwright raised their Q2 2026 EPS estimates for Lexicon Pharmaceuticals in a note issued to investors on Friday, May 8th. HC Wainwright analyst J. Pantginis now anticipates that the biopharmaceutical company will post earnings of ($0.05) per share for the quarter, up from their previous estimate of ($0.07). HC Wainwright currently has a “Buy” rating and a $6.00 target price on the stock. The consensus estimate for Lexicon Pharmaceuticals’ current full-year earnings is ($0.19) per share. HC Wainwright also issued estimates for Lexicon Pharmaceuticals’ Q3 2026 earnings at ($0.05) EPS, Q4 2026 earnings at ($0.06) EPS, FY2026 earnings at ($0.16) EPS, FY2028 earnings at ($0.17) EPS, FY2029 earnings at ($0.19) EPS and FY2030 earnings at ($0.10) EPS.
Several other research analysts have also recently issued reports on LXRX. Weiss Ratings reissued a “sell (d-)” rating on shares of Lexicon Pharmaceuticals in a report on Thursday, January 22nd. Citigroup lifted their price objective on shares of Lexicon Pharmaceuticals from $2.30 to $3.10 and gave the company a “buy” rating in a report on Monday. Two investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $4.55.
Lexicon Pharmaceuticals Trading Up 15.5%
Shares of Lexicon Pharmaceuticals stock opened at $2.31 on Tuesday. The company has a debt-to-equity ratio of 0.24, a current ratio of 18.80 and a quick ratio of 18.77. The firm has a fifty day moving average price of $1.68 and a 200 day moving average price of $1.46. Lexicon Pharmaceuticals has a 1 year low of $0.51 and a 1 year high of $2.47. The stock has a market cap of $1.03 billion, a PE ratio of -33.00 and a beta of 0.97.
Lexicon Pharmaceuticals (NASDAQ:LXRX – Get Free Report) last posted its quarterly earnings data on Thursday, May 7th. The biopharmaceutical company reported $0.00 EPS for the quarter, topping the consensus estimate of ($0.04) by $0.04. Lexicon Pharmaceuticals had a negative net margin of 37.46% and a negative return on equity of 18.64%. The business had revenue of $21.10 million during the quarter, compared to the consensus estimate of $9.79 million.
Institutional Inflows and Outflows
A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Bank of New York Mellon Corp increased its stake in shares of Lexicon Pharmaceuticals by 43.6% during the first quarter. Bank of New York Mellon Corp now owns 27,459 shares of the biopharmaceutical company’s stock worth $43,000 after purchasing an additional 8,335 shares in the last quarter. R Squared Ltd increased its stake in shares of Lexicon Pharmaceuticals by 45.0% during the first quarter. R Squared Ltd now owns 67,526 shares of the biopharmaceutical company’s stock worth $105,000 after purchasing an additional 20,947 shares in the last quarter. Virtu Financial LLC purchased a new stake in shares of Lexicon Pharmaceuticals during the fourth quarter worth about $42,000. Invesco Ltd. increased its stake in shares of Lexicon Pharmaceuticals by 14.1% during the fourth quarter. Invesco Ltd. now owns 594,883 shares of the biopharmaceutical company’s stock worth $684,000 after purchasing an additional 73,480 shares in the last quarter. Finally, Millennium Management LLC increased its stake in shares of Lexicon Pharmaceuticals by 25.9% during the fourth quarter. Millennium Management LLC now owns 4,821,733 shares of the biopharmaceutical company’s stock worth $5,545,000 after purchasing an additional 991,073 shares in the last quarter. Hedge funds and other institutional investors own 74.70% of the company’s stock.
Insiders Place Their Bets
In other news, Director Raymond Debbane acquired 100,000 shares of the business’s stock in a transaction on Monday, February 23rd. The stock was bought at an average price of $1.47 per share, with a total value of $147,000.00. Following the completion of the acquisition, the director owned 1,904,186 shares of the company’s stock, valued at approximately $2,799,153.42. This represents a 5.54% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders have acquired a total of 252,000 shares of company stock valued at $369,980 over the last three months. 14.00% of the stock is currently owned by insiders.
Key Lexicon Pharmaceuticals News
Here are the key news stories impacting Lexicon Pharmaceuticals this week:
- Positive Sentiment: Citigroup raised its price target on Lexicon Pharmaceuticals from $2.30 to $3.10 and kept a buy rating, signaling more upside potential for NASDAQ: LXRX. Article: Citigroup raises price target on Lexicon Pharmaceuticals
- Positive Sentiment: HC Wainwright maintained a buy rating and $6.00 price target while raising longer-term EPS estimates for FY2026, FY2028, FY2029, and FY2030, suggesting improving outlook beyond the near term for NASDAQ: LXRX.
- Neutral Sentiment: HC Wainwright also cut its Q3 and Q4 2026 EPS estimates, showing that near-term profitability expectations remain under pressure even as the longer-term view improved for NASDAQ: LXRX.
Lexicon Pharmaceuticals Company Profile
Lexicon Pharmaceuticals, Inc is a biopharmaceutical company focused on the discovery and development of novel medicines through its proprietary genome biology platform. By leveraging large-scale gene knockout libraries, the company identifies potential therapeutic targets and advances them through preclinical and clinical development. Lexicon’s approach emphasizes the translation of genetic insights into targeted therapies for a range of human diseases.
The company’s most advanced product is telotristat ethyl (sold under the brand name XERMELO), an oral treatment approved for the management of carcinoid syndrome diarrhea in patients inadequately controlled by somatostatin analog therapy.
See Also
- Five stocks we like better than Lexicon Pharmaceuticals
- Sell in May and Go Away—Starting With These 3 Stocks
- Before the Moon Base Gets Built, These 4 Companies Win
- Industrial Buybacks: Top Homebuilding Supplier Leads Buyback Increases
- 3 Stocks That Win If Inflation Surprises to the Downside
Receive News & Ratings for Lexicon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexicon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
